B

Biorender

Online platform for life-science illustrations

Overview

BioRender provides an online platform that helps scientists create professional scientific figures. It features a browser-based editor with thousands of icons and templates across 30+ life sciences fields, enabling quick, publication-ready figures for papers, presentations, and teaching materials. Users customize icons and templates via a comprehensive library, with subscription plans and enterprise options for different needs. Its goal is to speed up and simplify the creation of clear, high-quality scientific visuals for research and education, standing out through life-science–specific assets and ease of use.

YC Company

Work here?Claim your company

About Biorender

Simplify's Rating
Why Biorender is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Enterprise SoftwareBiotechnologyEducationHealthcare

Company Size

201-500

Company Stage

Series A

Total Funding

$17.3M

Headquarters

Toronto, Canada

Founded

2017

Get referred to Biorender

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • December 2025 Dimension Capital investment valued BioRender at $900 million with employee liquidity.
  • May 2026 Grant Support Initiative supported 60 winners across 524 institutions and $1.01 billion.
  • BioRender reported profitability and over 100 employees took liquidity in December 2025.

What critics are saying

  • BioRender's September 2026 terms tighten copyright controls, inviting academic backlash and churn.
  • Graphing attacks GraphPad Prism and risks price compression from entrenched scientific software vendors.
  • A licensing revolt or AI-native substitute could cripple BioRender's template moat by 2027.

What makes Biorender unique

  • BioRender's 40,000-plus icons and templates define science-specific visual language in 30-plus fields.
  • October 2025 Anthropic partnership embeds BioRender visuals directly into Claude for Life Sciences.
  • May 2026 Graphing bundles statistics, data prep, and figures inside one browser workspace.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$17.3M

Below

Industry Average

Funded Over

4 Rounds

Notable Investors:
Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
$15M
$17M
$30M

Benefits

  • Remote Work Options
  • Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-4%
Business Wire
Oct 6th, 2026
BioRender launches Leo, world's first AI agent for building accurate scientific research images

BioRender has launched Leo, an AI agent designed specifically for creating scientific figures. Unlike general-purpose AI image generators, Leo guides researchers through a structured process of planning, sketching, and building scientific illustrations. The tool addresses growing concerns about AI-generated scientific images appearing in publications with errors. Leo asks researchers focused questions about their figure's purpose and audience, then provides sketches for approval before building the final image. All elements remain editable, allowing scientists to correct details without re-prompting. BioRender CEO Shiz Aoki emphasised that science requires precision, which general AI tools often cannot provide. Leo is now available to all BioRender users. The company, founded in 2017, serves over 4 million scientists with its platform of vetted scientific icons and templates.

BioRender
Oct 6th, 2026
BioRender unveils the world's first AI agent that builds images for scientific research.

BioRender unveils the world's first AI agent that builds images for scientific research. As inaccurate images from general-purpose AI begin to undermine trust in science, Leo by BioRender offers researchers a fast, accurate, and editable alternative Toronto - October 6, 2026 - BioRender, the first scientific communication platform to standardize the visual language of biology, today announced the launch of Leo by BioRender, the world's only AI agent built specifically for scientific figures. Leo is designed to solve an emerging and critical problem: the erosion of trust in science caused by a proliferation of AI-generated images. As AI-generated images proliferate, trust in science erodes. AI image generation is advancing at a breakneck pace, with new models arriving from major labs and startups every month. But researchers have quickly discovered that general-purpose AI doesn't have the necessary context or design expertise for science. It's as predictable as a slot machine: on rare occasions it gets it right, but it's often a game of re-prompting and disappointment (and token costs). More critically, general-purpose AI is now the driver behind a growing integrity issue, with erroneous images finding their way into websites, search results, and scientific publications. How BioRender is taking a different approach. With 20+ years of expertise in effective science communication, BioRender is bringing a different approach to the challenge of AI-generated scientific images. Its team has developed Leo, the first AI agent purpose-built for scientific figure-making. Instead of repeated prompting, Leo guides researchers as they plan, sketch, and build a figure that's accurate, clear, and fully editable: * Leo plans before it draws. Researchers describe what a figure needs to achieve, then Leo asks focused questions about its audience, purpose, and other specifications, so nobody has to rewrite the same prompt over and over. * Researchers approve sketches before Leo builds them. Leo shows researchers a rough sketch that they can mark up, edit, and trim of unnecessary details, helping to keep costs low. * Leo builds with figure-making expertise. Once a sketch is approved, Leo builds a figure, keeping icon scale and style consistent, lining up panels, setting clear label hierarchies, and placing arrows to show relationships and sequences. * Every element stays editable. Each label, arrow, icon, and shape is its own object on the BioRender canvas, so researchers can correct a protein name, update a label, and ensure every other detail is accurate, without needing to re-prompt or worry about a single fix changing other parts of their figure. How it works: Leo guides researchers as they plan, sketch, and build scientific figures - the same way a trained medical illustrator would. About BioRender Unlike chemistry or electrical engineering, biology operated without a standard visual language well into the 21st century, with life scientists relying on hand-drawn diagrams and clip-art figures. BioRender is the platform that solved that problem, and it's the company defining how scientific communication remains accurate in an era of AI proliferation. Co-founded in 2017 by Shiz Aoki, Ryan Marien, and Katya Shteyn, BioRender's team of medical illustrators, PhD scientists, and engineers is creating the first suite of purpose-built AI tools designed to accelerate scientific communication and maintain accuracy and trust. Rooted in the world's largest library of vetted icons and customizable templates, BioRender is used today by more than 4 million scientists and 15 Nobel-Prize winning labs to turn complex science into accurate, publication-quality figures. As AI continues to increase the pace of research, BioRender is closing the gaps between discovery, understanding, and impact. Learn more at biorender.com.

BioRender
Jan 13th, 2026
Rewarding Our Team as BioRender Hits $900M Valuation

BioRender announces a $900M valuation and employee liquidity, reflecting our belief that the people building science’s visual language should share in the value they create.

Sidley Austin
Jan 7th, 2026
BioRender raises strategic investment from Dimension Capital at $900M valuation

BioRender, a scientific communication platform, has secured a strategic investment from Dimension Capital that values the company at approximately $900 million. The Toronto-based company, which aims to accelerate learning, discovery and scientific communication, provided liquidity to employees as part of the transaction. BioRender's platform enables researchers and scientists to create and share visual scientific content. The investment from Dimension Capital will support the company's mission to improve how scientific information is communicated and shared across the research community. Sidley Austin represented BioRender in the transaction, with a team led by Michael Podolny from the firm's Emerging Companies and Venture Capital practice.

Forbes
Apr 29th, 2025
Wine News Of The Month

Wine and the pope; wine and heart health; wine and GenZ. It’s [mostly] all about wine this monthPope Francis praised Italian wine producers last year at an industry event VinitalyWhile the death of Pope Francis has touched people across the globe, perhaps Italian wine producers are feeling the loss a little more keenly. Last year the pope addressed a group of more than 100 Italian wine producers who were granted special audience with the pontiff during an industry promotional event. Though Argentine, the pope was of Italian descent, with his father originating from Asti, the heart of Piemonte’s wine country. The pope told the producers yours is “certainly a significant presence” in terms of production and employment, but also recognized their diligence in wisely using “wine, the land, farming skills and entrepreneurial activity, [which] are gifts from God.” Bringing it a more secular level, he praised the producers for “the fundamental lines along which you have chosen to move – care for the environment, work and healthy consumer habits – indicate an attitude centered on respect, at various levels.”The special Vatican wine EL PAISIn related news, wine-searcher.com makes note that the election of a new pope may affect the fortunes of Spanish winery Heras Cordón in Rioja, which has been the exclusive supplier of wine for the Vatican since 2001 under the selection of John Paul II and continued by the subsequent popes. The only winery in Spain to hold the official Vatican supplier certificate produces 2000 bottles of the Vatican wine per year

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Biorender right now.

Find jobs on Simplify and start your career today

We update Biorender's jobs every few hours, so check again soon! Browse all jobs